Best Peptides for Sexual Health

Sexual dysfunction — encompassing reduced desire, arousal difficulties, and performance issues — affects a significant proportion of adults across all age groups and represents one of the most undertreated areas in medicine. Conventional pharmacological options are limited: PDE5 inhibitors (Viagra, Cialis) address the vascular mechanics of erection in men but do not touch desire or arousal; hormonal therapies carry substantial side effect profiles; and for women with hypoactive sexual desire disorder, approved pharmaceutical options are few and often poorly tolerated.

Peptides targeting the melanocortin receptor system in the brain represent a fundamentally different approach. Rather than acting on the peripheral vasculature or hormonal axis, they work centrally — modulating the neurochemical pathways in the hypothalamus that generate desire, arousal, and sexual motivation. This central mechanism is why PT-141 can work when PDE5 inhibitors fail, and why it produces effects in both sexes through a mechanism that is not sex-hormone dependent.

The sexual function peptide space is unusually polarized in terms of evidence quality. At one end is PT-141 (bremelanotide), an FDA-approved drug with completed Phase III trials, a known safety profile, and prescription availability. At the other end is Melanotan II — a compound with strong subjective user reports of arousal effects but no completed clinical trials for sexual function, no regulatory approval anywhere, and documented serious risks. Understanding this spectrum is essential for making an informed decision.

Critical note: PT-141 is FDA-approved as Vyleesi and available by prescription. All other peptides in this guide lack FDA approval for sexual function indications. Melanotan II in particular carries documented risks that should be carefully understood before consideration. Physician involvement is strongly recommended.

How We Ranked These Peptides

Rankings weight four criteria specific to sexual health applications:

1. Regulatory approval and clinical evidence. An FDA-approved drug with Phase III trial data ranks categorically above unregulated compounds with only Phase I or preclinical data.
2. Mechanism specificity. Peptides with direct central nervous system mechanisms targeting sexual desire and arousal rank above those acting through indirect hormonal pathways.
3. Safety profile. Given the elective nature of sexual function optimization, safety considerations carry higher weight than in disease treatment contexts.
4. Practical accessibility. Prescription availability through licensed physicians and pharmacies offers meaningful quality assurance advantages over unregulated research chemical markets.

1. PT-141 (Bremelanotide/Vyleesi), Best Overall for Sexual Dysfunction

PT-141, known generically as bremelanotide and commercially as Vyleesi, is a synthetic cyclic heptapeptide that the FDA approved in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It holds the top position not just because of its regulatory status, but because it represents the most sophisticated pharmacological approach to sexual dysfunction currently available — working through a mechanism that addresses desire at its neurological origin rather than the peripheral consequences of arousal.

The origins of PT-141 trace directly to Melanotan II research at the University of Arizona in the 1980s. When researcher Dr. Mac Hadley accidentally self-administered double the intended dose of Melanotan II and experienced an eight-hour erection alongside severe nausea, it redirected the entire research program toward sexual dysfunction. Palatin Technologies later synthesized bremelanotide, an active metabolite of Melanotan II, specifically designed to concentrate activity at the central melanocortin receptors (MC3R and MC4R) that mediate sexual function while minimizing MC1R-mediated tanning effects and reducing the nausea and blood pressure concerns of its parent compound.

The Central Nervous System Mechanism

PT-141 operates through an entirely different pathway than any other pharmacological treatment for sexual dysfunction. PDE5 inhibitors like sildenafil (Viagra) act peripherally: they block the enzyme that breaks down cGMP in penile vascular smooth muscle, maintaining vasodilation in response to existing arousal. They enhance the vascular response to sexual stimulation but do nothing for desire itself.

PT-141 acts upstream. MC4R and MC3R receptors are densely expressed in the paraventricular nucleus (PVN) of the hypothalamus — a region that integrates hormonal signals, emotional state, and sensory input to generate sexual motivation and drive. When PT-141 activates these receptors, it triggers cAMP signaling cascades that modulate dopaminergic pathways involved in desire, arousal, and motivation. This produces both the motivational (wanting) and physiological (genital blood flow) components of the sexual response.

MC4R knockout studies in animals confirmed that MC4R activation is essential for melanocortin agonist-induced erectile responses — animals lacking MC4R showed no erection responses to melanocortin peptides. This mechanistic confirmation strengthens the causal relationship between MC4R activation and sexual function effects.

The clinical implication is significant: PT-141 can address desire-based dysfunction where PDE5 inhibitors cannot, and its mechanism is independent of nitric oxide signaling pathways. This means it can produce benefit even in cases of erectile dysfunction refractory to PDE5 inhibitors — not by replacing the vascular mechanism but by activating the upstream neurological drive that the vascular response depends on.

Clinical Evidence

The FDA approval of Vyleesi was based on the RECONNECT Phase III program: two identical randomized, double-blind, placebo-controlled, multicenter trials evaluating bremelanotide 1.75 mg versus placebo in 1,267 randomized premenopausal women with acquired, generalized HSDD across 24 weeks of on-demand treatment.

Both studies met both coprimary endpoints. Bremelanotide produced statistically significant increases in sexual desire scores (Female Sexual Function Index desire domain, FSFI-D; P < 0.001) and statistically significant reductions in distress related to low desire (FSDS-DAO-13; P < 0.001) compared to placebo. Approximately 25% of bremelanotide-treated patients achieved a clinically meaningful improvement in desire versus 17% of placebo-treated patients. An open-label extension study confirmed maintained improvements in desire and reduced distress with continued on-demand use, with no new safety signals.

For men, a Phase IIB randomized controlled trial demonstrated positive erectile responses in 33.5% of bremelanotide-treated patients versus 8.5% on placebo. A separate salvage study in sildenafil non-responders showed that bremelanotide co-administered with sildenafil produced significantly enhanced erectile responses compared to sildenafil alone. Real-world clinical data from sexual medicine practices report improvements in male desire (39% of responders), erectile function (52%), orgasm (17%), and reduced performance anxiety (39%). Palatin Technologies has an ongoing Phase II co-administration program evaluating bremelanotide combined with PDE5 inhibitors for refractory male erectile dysfunction.

Dosage and Administration

FDA-approved dosing (women, HSDD):

• 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity
• Maximum one dose per 24-hour period
• Maximum 8 doses per month

Off-label dosing (men, clinical practice):

• 1.75 mg subcutaneously is the most commonly used off-label dose for men, consistent with the Phase IIB trial
• Some clinicians start at 0.5 to 1 mg for first-time users to assess nausea tolerance
• Anti-nausea medication (ondansetron 4 to 8 mg taken 30 minutes before PT-141) can substantially reduce the nausea that affects approximately 40% of first-dose users

Timing: Effects begin within 30 to 60 minutes of injection (peak plasma concentration), with maximal therapeutic effects at 1 to 4 hours post-dose. Biological effects on sexual function persist 6 to 8 hours, substantially longer than the plasma half-life of approximately 2.7 hours, reflecting receptor residence time and downstream neurochemical changes. Many users find injecting 1 to 2 hours before activity provides optimal timing.

Nausea management: Nausea is most common with the first dose and diminishes with subsequent use. It can be preemptively managed with ondansetron and by starting with lower doses. Administering after a light meal (rather than fasting) may also help, though this has not been formally studied.

Limitations: Nausea in 40% of patients (first dose), diminishing with use. Transient blood pressure elevation contraindicated with uncontrolled hypertension or cardiovascular disease. Research-grade PT-141 from unregulated sources lacks the quality guarantees of the FDA-approved Vyleesi auto-injector. Banned by WADA under broad peptide hormone language (though not listed by name on the 2025 list).

2. Melanotan II, Powerful Effects with Significant Risk

Melanotan II (MT-II) is the parent compound from which PT-141 was derived. Its sexual arousal effects are well-documented — in the original clinical research by Wessells and colleagues, MT-II produced erections in 80% of men with psychogenic erectile dysfunction in a placebo-controlled crossover study, versus 33% of men receiving PT-141 in its Phase IIB trial. The broader melanocortin receptor profile of MT-II, which activates MC1R through MC5R rather than concentrating on MC3R and MC4R, produces stronger and faster subjective arousal responses in many users alongside its pronounced tanning effects.

Understanding why PT-141 ranks above MT-II despite these seemingly superior arousal effects requires a clear-eyed assessment of the risk profile difference.

The Evidence for Sexual Function

The Wessells 1998 study, published in the Journal of Urology, was a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction. MT-II produced erections in 80% of participants. Dose-dependent erections lasting 1 to 5 hours were observed. This study directly contributed to the development of bremelanotide and confirmed the central mechanism of action. A Phase I clinical trial (Dorr et al., 1996) established the basic dose-response and early safety profile in healthy volunteers.

Beyond these early studies, MT-II has not been evaluated in controlled Phase II or III trials for sexual dysfunction. The drug development path diverged toward PT-141/bremelanotide specifically because MT-II's broader receptor activity produced an unacceptable side effect profile for regulatory approval. The compound that reached FDA approval is the refined, more receptor-selective version.

The Receptor Profile Difference

MT-II binds MC1R, MC3R, MC4R, and MC5R. PT-141 was specifically engineered to reduce MC1R activity while maintaining MC3R and MC4R activity. This distinction drives the key differences between the two compounds:

• MC1R activation (MT-II) → tanning: Melanocyte activation produces eumelanin, causing progressive skin darkening. Existing moles and freckles deepen significantly. This is the basis for MT-II's reputation as a tanning peptide.
• MC4R/MC3R activation (both) → sexual arousal and appetite suppression: The central sexual function and appetite-regulating effects are shared, though MT-II's broader MC receptor activation may produce stronger overall stimulation.
• MC5R activation (MT-II) → exocrine gland effects: MC5R is expressed in sweat, lacrimal, and sebaceous glands; activation contributes to flushing and facial redness.

Risks That Must Be Understood

Melanotan II carries risks that go beyond the nausea and blood pressure concerns of PT-141:

Melanoma risk. Multiple published case reports in peer-reviewed journals, including the British Journal of Dermatology, document melanomas arising during MT-II use. Both the UK's MHRA and Australia's TGA have issued formal safety warnings specifically citing melanoma risk. Definitive population-level causality has not been established through large-scale epidemiological studies, but the evidence is substantially stronger than theoretical. MT-II directly stimulates melanocyte proliferation through MC1R — the same receptor whose gain-of-function mutations are associated with increased melanoma risk. Individuals with numerous atypical moles, fair skin (Fitzpatrick type I), or personal or family history of melanoma face elevated risk.

Priapism. The Wessells 1998 study documented dose-dependent erections lasting 1 to 5 hours. Priapism — erection exceeding 4 hours — is a urological emergency: delayed treatment leads to permanent erectile dysfunction through ischemic damage to erectile tissue. The risk is real and documented.

Unregulated supply. MT-II has no approved pharmaceutical pathway in any country. Every available product is sourced from unregulated chemical manufacturers. Third-party testing of purchased MT-II products in multiple studies has found significant variation in purity, potency, and the presence of contaminants. There are no manufacturing standards, no batch testing requirements, and no recourse if a product is contaminated.

International legal status. In Australia, MT-II is technically Schedule 4 (prescription-only) but explicitly not approved for any therapeutic use, making importation prohibited. In the UK, sale for human consumption is illegal under medicines regulations. In the EU, it is unauthorized. In the US, it occupies the same research chemical gray area as most unapproved peptides but is not a controlled substance.

Best for: Users who have already used PT-141 successfully and are seeking stronger tanning effects alongside arousal; research contexts. Not recommended as a primary choice for sexual health optimization given the risk profile relative to PT-141.

Typical dosage: Initial tolerance assessment dose of 0.1 mg. Escalating to 0.25 mg for sexual function. Tanning protocols use 0.5 to 1 mg two to three times weekly with UV exposure. These protocols are derived entirely from community use — the only clinical studies used weight-based dosing in very small groups.

Limitations: No Phase II or III clinical trials for any indication. Documented melanoma risk with formal regulatory warnings. Priapism risk (medical emergency). No regulatory approval anywhere. Unregulated supply chain. Banned by WADA.

3. Kisspeptin-10, Emerging Upstream Hormonal Approach

Kisspeptin-10 is a 10-amino acid fragment of the kisspeptin neuropeptide family, encoded by the KiSS1 gene, that acts as a master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin neurons in the hypothalamus are the primary activators of GnRH (gonadotropin-releasing hormone) neurons — the upstream signal that drives LH, FSH, and ultimately testosterone and estrogen production. The therapeutic rationale for kisspeptin in sexual health is that it acts one step further upstream than GnRH analogs, at the neuroendocrine level where the reproductive axis is most finely regulated.

The mechanism is distinct from all other peptides in this guide. PT-141 and Melanotan II act on melanocortin receptors in the hypothalamus to drive arousal through dopaminergic pathways. Kisspeptin-10 acts on Kiss1R receptors on GnRH neurons to stimulate the hormonal cascade that maintains sexual desire, function, and reproductive capacity through testosterone and estrogen. These are complementary mechanisms that target different aspects of sexual neurophysiology.

Human research on kisspeptin is more substantive than its preclinical-stage reputation suggests. Intravenous kisspeptin administration in men with hypogonadotropic hypogonadism has been shown to restore pulsatile LH secretion and elevate testosterone levels. Studies in premenopausal women with hypothalamic amenorrhea — a condition where psychological or nutritional stress disrupts GnRH pulsatility — showed that kisspeptin infusion restored LH pulsatility and hormonal cycling. Published Phase I and Phase II studies exist, placing kisspeptin ahead of many peptides in terms of human evidence, though no completed efficacy trials have established a clinical indication.

A particularly interesting human study demonstrated that intravenous kisspeptin enhanced sexual brain processing in both men and women in a controlled experimental setting — participants showed increased activation of brain regions associated with sexual arousal in response to erotic stimuli after kisspeptin versus placebo. This finding directly links kisspeptin to central sexual arousal pathways beyond its role in gonadotropin regulation.

The limitation for practical use is route of administration. Research studies have primarily used intravenous infusion, which is not practical for real-world use. Subcutaneous kisspeptin-10 is being studied as a more accessible route, and early data suggests subcutaneous administration can elevate LH and testosterone, though the pharmacokinetics require more frequent dosing than IV to maintain hormonal effects. No established subcutaneous protocol has been validated in completed clinical trials.

Kisspeptin is most relevant for individuals with suspected hypothalamic dysfunction — conditions where the reproductive axis is blunted by stress, nutritional deficiency, excessive exercise, or subclinical hypothyroidism — rather than for individuals with a normally functioning HPG axis who want to amplify arousal acutely. For the latter, PT-141 has a more direct and better-evidenced mechanism.

Best for: Hypothalamic amenorrhea and low LH/FSH states (clinical), potential hormonal optimization in individuals with blunted HPG axis function, research protocols exploring upstream neuroendocrine interventions.

Typical dosage: Research has primarily used weight-based IV dosing (0.1 to 1 mcg/kg). Subcutaneous protocols are being developed but have not been validated in completed clinical trials. Not yet standardized for practical use.

Limitations: No completed Phase III trials. No regulatory approval for any indication. Practical administration challenges (IV in research settings; subcutaneous protocols not yet established). Less immediately relevant to arousal than PT-141's direct CNS mechanism. Emerging rather than established.

4. Growth Hormone Peptides, Best for Indirect Hormonal Sexual Health Optimization

Growth hormone secretagogues — primarily Ipamorelin and CJC-1295 — occupy a distinct and important position in sexual health. They do not directly activate sexual arousal pathways. They work instead through the hormonal environment that sustains sexual function over time: growth hormone, IGF-1, body composition, sleep quality, and the downstream effects of optimized metabolic function on testosterone and estrogen production.

The connection between GH/IGF-1 and sexual function operates through several pathways:

Testosterone support. Adequate GH and IGF-1 are important for Leydig cell function in men — the testicular cells that produce testosterone. GH deficiency is associated with reduced testosterone in men. Restoring GH/IGF-1 to physiological levels through secretagogues may support testosterone production, though this effect is more relevant in individuals with actual GH deficiency than in those with normal GH status.

Estrogen metabolism. In women, IGF-1 influences ovarian function and estrogen synthesis. Age-related decline in GH correlates with the hormonal changes that contribute to reduced sexual desire in peri- and post-menopausal women.

Body composition effects. Elevated GH and IGF-1 promote lean mass accrual and fat loss. Body composition changes driven by GH peptide use — reduced visceral fat, improved muscle mass — are associated with improved sexual function scores, likely through both mechanical and psychological mechanisms.

Sleep and recovery. GH secretagogues enhance slow-wave sleep quality, which is when the majority of pulsatile GH release occurs. Improved sleep quality has direct effects on testosterone production (which peaks during sleep) and on libido, which is profoundly sensitive to sleep deprivation.

Nitric oxide and vascular function. GH and IGF-1 stimulate nitric oxide synthase activity, improving endothelial function and penile blood flow — relevant for the erectile vascular component even though the mechanism is indirect compared to PDE5 inhibitors.

Ipamorelin is the preferred GHRP for sexual health applications because of its clean selectivity profile: it stimulates GH release without significantly elevating cortisol or prolactin. Cortisol elevation suppresses testosterone production and reduces libido. Prolactin elevation — which occurs with some GHRPs — directly suppresses sexual desire and can cause erectile dysfunction in men. Ipamorelin avoids these counterproductive effects.

CJC-1295 acts on a distinct pituitary receptor pathway from Ipamorelin (GHRH receptor versus ghrelin receptor), and their combination produces synergistic GH release that neither achieves alone. This combination is the most widely used GH peptide protocol and provides the most sustained IGF-1 elevation.

Clinical evidence specifically linking Ipamorelin or CJC-1295 to sexual function improvement is limited. The connection is supported by the established literature on GH deficiency and sexual dysfunction and by the indirect mechanisms described above, but no dedicated clinical trials have evaluated these peptides for sexual outcomes.

Best for: Long-term sexual health optimization in the context of age-related hormonal decline, supporting testosterone and estrogen production indirectly, improving sleep and recovery as foundations for libido, body composition optimization for sexual confidence and vascular health.

Typical dosage: Ipamorelin: 100 to 300 mcg, 1 to 3 times daily. CJC-1295: 100 mcg, 1 to 3 times daily. One dose before bedtime aligned with natural GH pulsatility. Cycle 8 to 12 weeks on, 4 weeks off.

Limitations: Indirect mechanism — effects on sexual function are downstream consequences of hormonal optimization, not direct arousal activation. Slower timelines than PT-141 or Melanotan II. Require cycling. Contraindicated with active malignancies.

The Melanocortin Receptor System: Understanding the Science Behind PT-141 and Melanotan II

Both PT-141 and Melanotan II work through the same receptor family, which is why understanding the melanocortin system provides essential context for choosing between them and using them safely.

Melanocortin receptors (MC1R through MC5R) are G-protein-coupled receptors distributed throughout the body and brain. Each subtype has a distinct expression pattern and functional profile:

• MC1R: Expressed on melanocytes in skin. Primary driver of tanning and pigmentation. Some modulatory role in inflammation.
• MC2R: The ACTH receptor on adrenal glands. Drives cortisol production. Not relevant to sexual function.
• MC3R: Expressed in hypothalamus and limbic system. Contributes to energy balance, inflammation modulation, and sexual function. Also relevant for the "wanting" dimension of sexual arousal.
• MC4R: Expressed in paraventricular nucleus and throughout CNS. Primary driver of melanocortin-mediated sexual arousal. Essential for erection response to melanocortin agonists (confirmed by knockout studies).
• MC5R: Expressed in exocrine glands. Contributes to flushing, sweating, and sebaceous effects.

PT-141 was specifically engineered to maximize MC3R and MC4R activity while reducing MC1R activity (less tanning) and minimizing MC5R effects. Melanotan II activates all five subtypes broadly, producing stronger MC4R stimulation alongside the MC1R tanning effects and MC5R exocrine effects.

This receptor profile difference explains the key practical distinction: PT-141 gives you the arousal mechanism without the tanning; Melanotan II gives you both, but with the full risk profile of MC1R activation including melanocyte stimulation, mole changes, and melanoma risk. Neither should be used with the other — the overlapping MC3R and MC4R activity would produce unpredictable additive or synergistic effects.

Safety and Legal Considerations

PT-141 (bremelanotide):

PT-141 is FDA-approved as Vyleesi and available by prescription in the United States. The FDA-approved product is supplied as a single-dose, pre-filled auto-injector with pharmaceutical manufacturing standards. Off-label prescribing for men is legal at physician discretion. Compounding pharmacy preparations are available for off-label use but lack the quality guarantees of the FDA-approved product.

Key precautions: Contraindicated in uncontrolled hypertension or known cardiovascular disease due to the transient blood pressure elevation. Blood pressure should be well-controlled before initiating therapy. Do not co-administer with naltrexone (PT-141 slows gastric motility and may alter naltrexone absorption). Maximum 8 doses per month.

Melanotan II:

Melanotan II has no approved pharmaceutical pathway in any country. The only products available are research chemicals from unregulated manufacturers. Quality verification through third-party HPLC testing is essential. Formal safety warnings have been issued by the UK MHRA and Australian TGA regarding melanoma risk specifically. Any user should have baseline dermatological assessment and monitoring during use. Men should be aware of priapism risk — erections exceeding 4 hours require emergency urological treatment.

WADA status: Melanotan II is explicitly prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). PT-141's WADA status is less clear — it is not listed by name on the 2025 Prohibited List, but as a synthetic peptide hormone analog and melanocortin receptor agonist it may fall under broader S2 language. Athletes should not use PT-141 without verifying current WADA status with their governing body.

Kisspeptin-10: Not approved for any indication. Research-grade only. Not known to be WADA-prohibited based on current list language, but this should be verified.

GH peptides (Ipamorelin, CJC-1295): Not FDA-approved; available through compounding pharmacies with prescription for anti-aging and performance indications in some states. Not WADA-prohibited by name, though WADA's S2 category includes broad language that may capture GH secretagogues depending on interpretation.

Conclusion

PT-141 (bremelanotide/Vyleesi) is the evidence-based first choice for peptide-based sexual function support. Its central nervous system mechanism — activating MC3R and MC4R in the hypothalamus to generate desire and arousal at the neurological level — is unique in pharmacology, working through pathways that PDE5 inhibitors cannot access. Its Phase III clinical trial data, FDA approval, and prescription availability give it a quality and safety profile that no other sexual function peptide can match.

Melanotan II's arousal effects are stronger in many users but come with documented risks — melanocyte activation and the associated melanoma risk, priapism, and an entirely unregulated supply chain — that represent a substantially worse risk-benefit calculation for the majority of users. It is not a better version of PT-141; it is a different compound with a broader and less controlled pharmacological profile.

Kisspeptin-10 represents genuine scientific promise for upstream HPG axis modulation and is worth watching as Phase II data matures, but it remains too early-stage for practical recommendations. Growth hormone peptides address sexual health at the hormonal foundation level — supporting the testosterone, estrogen, sleep quality, and body composition that underpin sexual function over the long term, rather than activating acute arousal acutely.

For anyone experiencing genuine sexual dysfunction, PT-141 through a licensed physician and the FDA-approved Vyleesi product is the right starting point. For those seeking foundational hormonal support, a thoughtfully dosed Ipamorelin and CJC-1295 protocol is the safest evidence-informed approach. Whatever the path, the unregulated research chemical market demands extreme caution — verification of purity, physician oversight, and honest risk assessment are not optional in a space where the stakes are this personal.